title: Management of the new patient with CML in chronic phase.
abstract: Imatinib has been the preferred initial therapy for newly diagnosed chronic myeloid leukemia (CML) patients for the last 10 years. Today, other tyrosine kinase inhibitors (TKIs) are licensed for first-line use. In this paper we analyze the pros and cons of the various alternatives to imatinib and try to give some advice on the management of the newly diagnosed patient.
authors: Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK. d.marin@imperial.ac.uk
authors: David
authors: D
authors: Marin
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000069439:Dasatinib; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib
references: J Clin Oncol. 2007 Sep 1;25(25):3908-14
references: 17761974
references: Cancer. 2010 Jan 15;116(2):377-86
references: 19924787
references: Lancet Oncol. 2011 Sep;12(9):841-51
references: 21856226
references: Am J Hematol. 2011 Jul;86(7):533-9
references: 21538470
references: Blood. 2008 Dec 1;112(12):4437-44
references: 18716134
references: Semin Hematol. 2010 Oct;47(4):312-8
references: 20875547
references: Lancet Oncol. 2010 Nov;11(11):1029-35
references: 20965785
references: Blood. 2012 Feb 2;119(5):1123-9
references: 22160483
references: N Engl J Med. 2010 Jun 17;362(24):2260-70
references: 20525995
references: J Clin Oncol. 2010 Jan 20;28(3):392-7
references: 20008621
references: Circulation. 2012 May 1;125(17):2128-37
references: 22451584
references: N Engl J Med. 2006 Dec 7;355(23):2408-17
references: 17151364
references: Blood. 2012 Jul 12;120(2):291-4
references: 22645182
references: J Clin Oncol. 2009 Dec 10;27(35):6041-51
references: 19884523
references: Int J Hematol. 2011 Oct;94(4):361-371
references: 21901399
references: Br J Haematol. 2008 May;141(5):745-7
references: 18331365
references: J Clin Oncol. 2012 Jan 20;30(3):232-8
references: 22067393
references: Curr Hematol Malig Rep. 2012 Jun;7(2):103-8
references: 22410764
references: Blood. 2011 Oct 27;118(17):4541-6; quiz 4759
references: 21803854
references: J Clin Oncol. 2011 Nov 10;29(32):4260-5
references: 21990394
references: J Clin Oncol. 2010 Jan 20;28(3):398-404
references: 20008620
references: N Engl J Med. 2010 Jun 17;362(24):2251-9
references: 20525993
references: Genes Chromosomes Cancer. 1995 Jun;13(2):110-4
references: 7542905